Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

SciMed chose to accept more market and regulatory risk in psychedelics because the clinical science looked strong, Matias says. He points to uncertainty over payer reimbursement and pharma acquisitions as the tradeoff for underwriting less technical risk. The FDA's openness, including breakthrough designations, made that bet feel more reasonable.

Related Insights

J&J's Spravato de-risked the complex delivery model for psychedelics by establishing a network of over 7,000 certified clinics. This pre-built infrastructure for in-office administration and monitoring provides a ready-made commercial pathway for new psychedelic therapies, solving a major scalability hurdle for the industry.

Recent acquisitions, such as Eli Lilly buying Atai and AbbVie buying Gigamesh, are the clearest signal that psychedelic therapies are no longer a niche R&D area. Major pharmaceutical companies now view the space as a core part of their growth strategy and a substantial business opportunity.

Eli Lilly, one of pharma's most powerful brands, acquiring psychedelics company Atai Beckley is a major validation for the entire sector. This move signals that previously controversial therapeutic areas are now open for M&A by top-tier, conservative pharma companies, potentially opening the floodgates for more deals.

While Compass's psilocybin shows strong Phase 3 data, its 6-8 hour in-office administration is a major commercial hurdle compared to J&J's Spravato (2 hours). The key investment thesis is that its significantly longer-lasting effect will justify the logistical complexity for patients, providers, and payers.

Eli Lilly acquired Atai Beckley, whose lead drug offers a more intense psychedelic experience but a much shorter duration than competitors like psilocybin. This highlights a key business calculation: reduced clinic time and monitoring costs can outweigh the risks of a more potent drug.

The public perception of a downturn in the psychedelic space, fueled by falling company valuations and a key FDA rejection, is misleading. Behind the scenes, the rate and quality of scientific publications and clinical trials are higher than ever, suggesting the underlying research is robust and accelerating.

Matias expects classic psychedelics may reach approval first, but says best-in-class compounds may be non-hallucinogenic. He cites Gilgamesh's AbbVie-linked program and Delix's positive Phase 1b data as evidence for this newer generation. The thesis is that first-in-class does not stay best-in-class by default, and he is bullish on the category.

For the next wave of psychedelic therapies, the pivotal regulatory question is treatment durability. The FDA's view on "as-needed" (PRN) dosing versus the fixed-interval schedule of approved drugs like Spravato will determine the commercial viability and clinical pathway for companies like Compass Pathways.

The psychedelic sector struggled for funding until Johnson & Johnson's Spravato was approved. This validation from a major pharmaceutical company for a similar “interventional compound” legitimized the entire space, making it significantly easier for startups like Atai to overcome investor skepticism and raise capital.

Psychedelic companies can avoid the cannabis industry's collapse by pursuing a medical, prescription-based model. This strategy allows for controlled supply, higher prices, and insurance coverage, creating a far more profitable market than the oversupplied, low-margin recreational space.

Psychedelic bets trade technical risk for reimbursement risk. | RiffOn